干酪乳杆菌细胞壁提取物在人源化IGHA1小鼠中诱导半乳糖缺陷型IgA1产生
研究构建了表达人IgA1重链的转基因小鼠(IGHA1+/+),在环境病原体暴露或干酪乳杆菌细胞壁提取物(LCWE)联合完全弗氏佐剂(CFA)刺激后,血清半乳糖缺陷型IgA1(Gd-IgA1)水平升高,并出现类似IgA肾病的肾小球病变;与补体H因子突变小鼠杂交后,LCWE刺激可导致白蛋白尿和血尿。
要点
- 人源化IGHA1小鼠在病原体或LCWE刺激后血清Gd-IgA1升高。
- LCWE诱导肾小球系膜区IgA1和C3沉积及系膜增生。
- 联合补体H因子突变可出现白蛋白尿和血尿。
核心结论
- LCWE联合CFA刺激IGHA1+/+小鼠可升高血浆Gd-IgA1并引起肾脏IgA1沉积。
- 结合补体H因子突变,小鼠出现类似临床IgA肾病的肾小球改变伴血尿和蛋白尿。
研究设计与样本
- 研究构建了转基因表达人IGHA1基因的人源化小鼠模型。
- IGHA1+/+小鼠与补体H因子杂合突变(FHW/R)小鼠杂交产生IGHA1+/+FHW/R小鼠。
- IGHA1+/+小鼠在出生后4个月内分别饲养于无菌、无特定病原体或常规环境以暴露不同水平病原体。
- 野生型C57BL/6J、IGHA1+/+和IGHA1+/+FHW/R小鼠在2月龄时接种LCWE混合CFA以建立IgA肾病模型。
主要发现
- IGHA1+/+小鼠暴露于病原体后,血液循环和黏膜部位的人IgA1水平升高。
- 与缓冲液对照相比,LCWE加CFA处理小鼠循环人IgA1水平中度升高一倍,人IgA1免疫复合物升高两倍。
- LCWE处理后血清Gd-IgA1水平升高四倍。
- IgA1铰链区O-糖肽分析证实低半乳糖基化,糖型种类与临床样本一致。
- LCWE诱导肾小球系膜区持续的IgA1和C3沉积,伴系膜扩张和细胞增多。
临床怎么用
- 该模型可用于研究Gd-IgA1的产生来源、生化特征和免疫反应性。
- 为IgA肾病发病机制及补体H因子相关病变提供体内研究工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: We generated a transgenic mouse model expressing the human IgA1 heavy chain, which has a hinge region with rich O-linked glycosylation. After inflammatory stimulation, the mouse model showed elevated galactose-deficient IgA1 levels in the serum. Coupled with complement H factor mutant, the mice model exhibited glomerular lesions, associated with hematuria and albuminuria like IgA nephropathy. BACKGROUND: IgA nephropathy is the most common primary glomerulonephritis worldwide, and there is emerging evidence linking galactose-deficient IgA1 (Gd-IgA1) to the pathogenesis of the disease. However, mouse models that can be used to study Gd-IgA1's origin of production, biochemical characteristics, and immune reactivity are lacking. METHODS: We generated a humanized IgA1 mouse model with transgenic expression of the human IGHA1 gene from the mouse chromosomal locus of IgA heavy chain. The IGHA1+/+ mice were crossed with complement factor H heterozygous mutant (FHW/R) to generate IGHA1+/+FHW/R mice. IGHA1+/+ mice were exposed to different levels of environmental pathogens in the first 4 months, as housed in germ-free, specific pathogen–free, or conventional environments. In addition, wild-type C57BL/6J mice, IGHA1+/+ mice, and IGHA1+/+FHW/R mice were inoculated with Lactobacillus casei cell wall extract (LCWE) mixed with complete Freund's adjuvant (CFA) at 2 months of age to develop a mouse model of IgA nephropathy. RESULTS: Elevated levels of human IgA1 in blood circulation and mucosal sites were observed in IGHA1+/+ mice from exposure to pathogens. Compared with buffer-treated control mice, LCWE plus CFA-treated mice had moderately elevated levels of circulating human IgA1 (by one-fold) and human IgA1 immune complexes (by two-fold). Serum Gd-IgA1 levels increased four-fold after LCWE treatments. Analyses of the O-glycopeptides of the IgA1 hinge region confirmed hypogalactosylation of IgA1, with the variety of the glycoforms matching those seen in clinical samples. Furthermore, LCWE induced persistent IgA1 and C3 deposition in the glomerular mesangial areas in association with mesangial expansion and hypercellularity, which are frequently observed in IgA nephropathy biopsies. The IGHA1+/+FHW/R mice stimulated with LCWE and CFA developed albuminuria and hematuria. CONCLUSIONS: We observed elevated plasma Gd-IgA1 levels with kidney deposition of IgA1 in the IGHA1+/+ mice after LCWE and CFA. In conjunction with factor H mutation, the mice exhibited severe glomerular alterations, associated with hematuria and albuminuria in resemblance of clinical IgA nephropathy.
引用
- Li R, Wang M, Li J, et al. Lactobacillus casei Cell Wall Extract and Production of Galactose-Deficient IgA1 in a Humanized IGHA1 Mouse Model. J Am Soc Nephrol. 2024. PMID: 39172518. doi:10.1681/ASN.0000000000000465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。